Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.83 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.83 |
| ▸ | BRD2 | P25440 | 4/20 | 0.83 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.83 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.83 |
| ▸ | DNER | Q8NFT8 | 2/20 | 0.83 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.83 |
| ▸ | JAK2 | O60674 | 1/20 | 0.83 |
| ▸ | BRD1 | O95696 | 1/20 | 0.83 |
| ▸ | CCL2 | P13500 | 1/20 | 0.83 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.83 |
| ▸ | EP300 | Q09472 | 1/20 | 0.83 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.83 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.83 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.83 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.83 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.83 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17059520 | 1.00 | BRD4 (0.83) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL17059521 | 0.92 | BRD4 (0.80) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL881223 | 0.92 | BRD4 (0.80) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL881282 | 0.91 | BRD4 (0.79) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL881208 | 0.91 | BRD4 (1.00) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL881473 | 0.91 | BRD4 (1.00) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL881227 | 0.91 | BRD4 (1.00) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL23317871 | 0.89 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL21349526 | 0.89 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL23317872 | 0.89 | BRD4 (0.80) | BRD4BRDTBRD2BRD3CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11666580-B2 | Mechanism of resistance to bet bromodomain inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666580-B2 | Mechanism of resistance to bet bromodomain inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-10925881-B2 | Treatment of conditions associated with hyperinsulinaemia | TENSHA THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200407371-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200368248-A1 | MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| WO-2011143651-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143657-A1 | MALE CONTRACEPTIVE COMPOSITIONS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143660-A2 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143669-A2 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA-FARBER CANCER INSTITUTE, INC (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | BRD4 2/4885BRDT 1/4885BRD2 4/4885 |
| US-11666580-B2 | Mechanism of resistance to bet bromodomain inhibitors | BET1, BRD2, BRD4 | BRD4 3/4885BRDT 12/4885BRD2 2/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | BRD4 205/4885BRDT 85/4885BRD2 287/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | BRD4 3192/4885BRDT 1771/4885BRD2 4023/4885 |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | MCL1, ABL1, FLT3 | BRD4 891/4885BRDT 3079/4885BRD2 1481/4885 |
| US-20200368248-A1 | MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS | BET1, BRD2, BRD4 | BRD4 3/4885BRDT 12/4885BRD2 2/4885 |
| US-20200407371-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | BAZ2A, BRD3, BRPF3 | BRD4 11/4885BRDT 12/4885BRD2 29/4885 |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | BRPF3, EP300, BRD3 | BRD4 4/4885BRDT 8/4885BRD2 9/4885 |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | BRD3, BRD2, BRD4 | BRD4 3/4885BRDT 16/4885BRD2 2/4885 |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | BAZ2A, BRD3, BRPF3 | BRD4 11/4885BRDT 12/4885BRD2 29/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | BRD4 205/4885BRDT 85/4885BRD2 287/4885 |
| US-10925881-B2 | Treatment of conditions associated with hyperinsulinaemia | GPR119, IAPP, SLC5A2 | BRD4 1068/4885BRDT 712/4885BRD2 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.